A comparison of the impact of isotope (125I vs. 103Pd) on toxicity and biochemical outcome after interstitial brachytherapy and external beam radiation therapy for clinically localized prostate cancer

There were no differences in acute or long-term genitourinary or gastrointestinal toxicity between 125I and 103Pd in combined modality therapy for prostate cancer. There may be less erectile toxicity with the use of 103Pd; however, additional followup of these patients is needed. There was no significant difference in 5-year prostate-specific antigen relapse-free survival between 103Pd and 125I.